Novartis shelves potential blockbuster pelacarsen as landmark study fails
Novartis AG is halting development of pelacarsen, an experimental cardiovascular drug, after a key study showed it failed to reduce heart attacks or strokes despite lowering cholesterol. The company will continue one mid-stage study for a different heart condition. The Lp(a) HORIZON trial, published in the New England Journal of Medicine, found no clinical benefit from the drug. According to Dr. Steven Nissen, the trial results were neutral, offering no harm or benefit.
How this was made
The 30-second read
Why it matters
The trial failure removes a potential multi‑billion‑dollar revenue stream and may pressure the stock while also affecting the broader cardiovascular‑therapy sector.
Market read
First report of a major cardiovascular outcomes trial miss; material for investors in Novartis and the biotech sector.
What to watch
The remaining mid‑stage study on calcific aortic valve stenosis may still yield a niche indication for pelacarsen.
Background
Novartis disclosed that its experimental drug pelacarsen dramatically lowered Lp(a) levels but did not improve clinical outcomes in a large Phase 3 trial.
Ticker impact
Novartis AG halted development of pelacarsen after the Phase 3 Lp(a) HORIZON trial failed to reduce cardiovascular events.
likely pressure as the market prices in the trial failure
The first disclosure of a major cardiovascular‑outcome trial miss is material and fresh, prompting immediate re‑valuation.
Market effects
Setback for Lp(a)‑targeting therapeutics and may dampen biotech R&D optimism in cardiovascular space.
European and Swiss markets could see modest declines in pharma stocks.
Potential ripple effect on global pharma equities as investors reassess cardiovascular pipeline risk.
Counterpoint
Some traders may view the price drop as an oversold entry point if they believe the valve‑calc study could still succeed.
Key entities
- companyNovartis AG
Swiss pharmaceutical giant, ticker NVS.
- clinical_trialLp(a) HORIZON trial
Phase 3 outcomes study for pelacarsen.
